ClinicalTrials.gg
CompletedNCT05033886DaylightUpdated Oct 26, 2024

A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause

A Phase 3 interventional study of fezolinetant and placebo in Vasomotor Symptoms, sponsored by Astellas Pharma Global Development, Inc.. Completed at 69 sites in 16 countries. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
453
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Study summary

This study is for women in menopause who have moderate to severe hot flashes. It is for women who are unable to use hormone replacement therapy (HRT). Menopause, a normal part of life, is the time after a woman's last period. Hot flashes often occur during menopause. They can disrupt a woman's daily life.

The study medicines (also called investigational products, or IP) are tablets of fezolinetant or placebo. An investigational product means that the product is not yet licensed. In this study, a placebo is a dummy treatment that looks like fezolinetant but does not have any medicine in it. The study will compare fezolinetant with the placebo to learn if fezolinetant reduces the number and severity of hot flashes.

Women that want to take part in the study will be given an electronic handheld device with an app to track their hot flashes. Some women may be able to use the app on their own smartphone. In the last 10 days before their next clinic visit, the women will record information about their hot flashes. They can take part in the study if they have an average of 7 or more moderate to severe hot flashes each day. Women will be picked for 1 of 2 treatments (fezolinetant or placebo) by chance alone.

Women who take part in the study will take 2 tablets every day for 24 weeks. Treatment will be double-blinded. That means that the women in the study and the study doctors will not know who takes which of the study medicines (fezolinetant or placebo). The women will continue recording information about their hot flashes on the electronic device or their phone. They will also use another device to answer questions about how hot flashes affect their daily life.

During the study, the women will visit their study clinic several times for a check-up. This will happen during Weeks 2, 4, 8, 12, 16, 20, 24, and 27. Some women may be able to have home visits instead, from Week 2 to Week 20. At the check-up, they will be asked if they have any medical problems. Other checks will include vital signs (heart rate, temperature and blood pressure) and some blood samples taken for laboratory tests. At some check-ups, the women will have a physical exam. In Week 2 and Week 24, the women will have an ECG to check their heart rhythm. Women who have a uterus will also have a test called a transvaginal ultrasound. A probe is gently placed inside the vagina. Sound waves will create a picture of the organs in the pelvis. This will allow the study doctor to look more closely at the uterus and surrounding organs.

The last check-up (at Week 27) will be 3 weeks after they take their last tablets of study medicine (fezolinetant or placebo).

02

Conditions studied

  • Vasomotor Symptoms

Keywords

  • ESN364
  • menopause
  • fezolinetant
  • vasomotor symptoms
03

In context

Lead sponsor

Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.

Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be seeking treatment or relief for vasomotor symptoms (VMS) associated with menopause and confirmed as menopausal per one of the following criteria at the screening visit:

    • Spontaneous amenorrhea for >= 12 consecutive months
    • Spontaneous amenorrhea for >= 6 months with biochemical criterion of menopause (follicle-stimulating hormone [FSH] > 40 IU/L)
    • Had bilateral oophorectomy >= 6 weeks prior to the screening visit (with or without hysterectomy)
  • Participant has VMS and is unsuitable to receive hormone replacement therapy (HRT) (HRT , HRT caution, HRT stoppers and HRT averse participants).
  • Participant has a minimum average of 7 moderate to severe hot flash's (HFs) (VMS) per day as recorded in the electronic diary during the last 10 days prior to randomization.
  • Participant is in good general health as determined on the basis of medical history, general physical examination, laboratory and other medical assessments.
  • Participant has a negative serology panel (including surface antigen, virus antibody and antibody screens).
  • Had hysterectomy without oophorectomy and who meets the biochemical criterion of menopause (FSH > 40 IU/L).

Exclusion criteria

Exclusion Criteria:

  • Participant uses a prohibited therapy for VMS (e.g., prescription, over-the-counter or herbal) prior to screening and for the duration of treatment with product (IP).
  • Participant has known documented substance abuse or alcohol addiction within 6 months of screening.
  • Participant has history of a malignant tumor within the last 5 years, except for basal cell carcinoma.
  • Participant has endometrial thickness > 8 mm on the locally read screening transvaginal ultrasound (TVU) or any findings that that would make the participant ineligible.
  • Participant has history of severe allergy, or intolerance to the IP and/or any of its .
  • Participant has a history of seizures or other convulsive disorders unless well controlled.
  • Participant has a medical condition or chronic disease (including history of neurological [including cognitive], renal, cardiovascular, gastrointestinal, pulmonary [e.g., moderate asthma], endocrine or gynecological disease) or that could confound interpretation of the study outcome.
  • Participant has any of the following: active liver disease, jaundice, elevated liver aminotransferases at screening ( [ALT] or aspartate aminotransferase [AST]), elevated total (TBL) or direct bilirubin (DBL) > 1.5 × (ULN), elevated (INR) > 1.5 (unless participant is receiving anticoagulant therapy) or elevated alkaline phosphatase (ALP). Participants with mildly elevated ALT or AST up to 1.5 × ULN can be enrolled if TBL and DBL are normal. Participants with mildly elevated ALP (up to 1.5 × ULN) can be enrolled if cholestatic liver disease is excluded and no cause other than fatty liver is diagnosed. Participants with Gilbert's syndrome with elevated TBL may be enrolled as long as DBL, and reticulocytes are normal.
  • Participant has creatinine > 1.5 × ULN or estimated using the Modification of Diet in Renal Disease formula \<= 59 mL/min per 1.73 m\^2 at the screening visit.
  • Participant has a history of suicide attempt or suicidal behavior within the last 12 months.
  • Participant has participated in another interventional study within the last 30 days prior to screening and for the duration of the study.
  • Participant who has been previously enrolled in a clinical study with fezolinetant.
  • Participant is unable or unwilling to complete the study procedures.
  • Participant has any condition makes the participant unsuitable for study participation.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
453 participants (actual)

Study arms

  • Experimental
    fezolinetant

    Participants receive fezolinetant 45 milligrams (mg) (one 30 mg tablet and one 15 mg tablet) orally once daily for 24 weeks of treatment.

    Drug: fezolinetant

  • Placebo comparator
    placebo

    Participants receive placebo matched to fezolinetant tablets orally once daily for 24 weeks of treatment.

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean change in the frequency of moderate to severe VMS from baseline at week 24

    The frequency of moderate to severe VMS is the number of moderate to severe VMS per 24 hours. A daily frequency per week is derived by taking the mean of the data over 7 days. Moderate VMS is defined as sensation of heat with sweating/dampness but is able to continue activity. Severe VMS is defined as sensation of intense heat with sweating, caused disruption of activity.

    Time frame: Baseline, week 24

Secondary outcomes

  1. Mean change in the severity of moderate to severe VMS from baseline at week 24

    Severity of moderate to severe VMS per day is calculated as follows: \[(number of moderate Hot Flashes (HFs) × 2) + (number of severe HFs/day × 3)\]/number of daily moderate/severe HFs. Moderate VMS is defined as sensation of heat with sweating but able to continue activity. Severe VMS is defined as sensation of intense heat with sweating, causing cessation of activity. Severity is zero for participants that have had no moderate or severe VMS. Higher score indicates greater severity. A negative change indicates a reduction/improvement.

    Time frame: Baseline, week 24

  2. Mean change in the patient-reported sleep disturbance by the Patient-reported Outcomes Measurement Information System Sleep Disturbance - Short Form 8b (PROMIS SD SF 8b total score) from baseline at week 24

    The PROMIS SD SF 8b assesses self reported sleep disturbance over the past 7 days and includes perceptions of restless sleep; satisfaction with sleep; refreshing sleep; difficulties sleeping, getting to sleep or staying asleep; amount of sleep; and sleep quality. Because it assesses the participants experience of sleep disturbance, the measure does not focus on specific sleep-disorder symptoms or ask participants to report objective measures of sleep (e.g., total amount of sleep, time to fall asleep and amount of wakefulness during sleep). Responses to each of the 8 items range from 1 (no disturbed sleep) to 5 (disturbed sleep), and the range of possible summed raw scores is 8 to 40. Higher scores on the PROMIS SD SF 8b indicate more of the disturbed sleep. A negative value indicates a better outcome.

    Time frame: Baseline, week 24

  3. Mean change in the frequency of moderate to severe VMS from baseline at weeks 1, 4, 8, 12, 16 and 20

    The frequency of moderate to severe VMS is the number of moderate to severe VMS per 24 hours. A daily frequency per week is derived by taking the mean of the data over 7 days. Moderate VMS is defined as sensation of heat with sweating/dampness but is able to continue activity. Severe VMS is defined as sensation of intense heat with sweating, caused disruption of activity.

    Time frame: Baseline, weeks 1, 4, 8, 12, 16 and 20

  4. Mean change in severity of moderate to severe VMS from baseline at weeks 1, 4, 8, 12, 16 and 20

    Severity of moderate to severe VMS per day is calculated as follows: \[(number of moderate HFs × 2) + (number of severe HFs/day × 3)\]/number of daily moderate/severe HFs. Moderate VMS is defined as sensation of heat with sweating/dampness but is able to continue activity. Severe VMS is defined as sensation of intense heat with sweating, causing cessation of activity. Severity is zero for participants that have had no moderate or severe VMS. Higher score indicates greater severity. A negative change indicates a reduction/improvement.

    Time frame: Baseline, weeks 1, 4, 8, 12, 16 and 20

  5. Mean percent change in the frequency of moderate to severe VMS from baseline at weeks 1, 4, 8, 12, 16, 20 and 24

    The frequency of moderate to severe VMS is the number of moderate to severe VMS per 24 hours. A daily frequency per week is derived by taking the mean of the data over 7 days. Moderate VMS is defined as sensation of heat with sweating/dampness but is able to continue activity. Severe VMS is defined as sensation of intense heat with sweating, caused disruption of activity.

    Time frame: Baseline, weeks 1, 4, 8, 12, 16, 20 and 24

  6. Number of participants with percent reduction of >/= 50% in the frequency of moderate to severe VMS from baseline at weeks 1, 4, 8, 12, 16, 20 and 24

    The frequency of moderate to severe VMS is the number of moderate to severe VMS per 24 hours. A daily frequency per week is derived by taking the mean of the data over 7 days. Moderate VMS is defined as sensation of heat with sweating/dampness but is able to continue activity. Severe VMS is defined as sensation of intense heat with sweating, caused disruption of activity.

    Time frame: Baseline, weeks 1, 4, 8, 12, 16, 20 and 24

  7. Number of participants with percent reduction of >/= 75% in the frequency of moderate to severe VMS from baseline at weeks 1, 4, 8, 12, 16, 20 and 24

    The frequency of moderate to severe VMS is the number of moderate to severe VMS per 24 hours. A daily frequency per week is derived by taking the mean of the data over 7 days. Moderate VMS is defined as sensation of heat with sweating/dampness but is able to continue activity. Severe VMS is defined as sensation of intense heat with sweating, caused disruption of activity.

    Time frame: Baseline, weeks 1, 4, 8, 12, 16, 20 and 24

  8. Number of participants with percent reduction at 100% in the frequency of moderate to severe VMS from baseline at weeks 1, 4, 8, 12, 16, 20 and 24

    The frequency of moderate to severe VMS is the number of moderate to severe VMS per 24 hours. A daily frequency per week is derived by taking the mean of the data over 7 days. Moderate VMS is defined as sensation of heat with sweating/dampness but is able to continue activity. Severe VMS is defined as sensation of intense heat with sweating, caused disruption of activity.

    Time frame: Baseline, weeks 1, 4, 8, 12, 16, 20 and 24

  9. Number of participants with Treatment Emergent Adverse Events (TEAEs)

    An AE is any untoward medical occurrence in a participant administered a study drug, which does not necessarily have to have a causal relationship with this treatment. An AE can be any unfavorable \& unintended sign, symptom, or disease temporally associated with the use of medicinal product (MP) whether considered related to MP. A TEAE was defined as an AE observed after starting administration of study intervention and up to 21 days after the last dose of study intervention.

    Time frame: From first dose to week 27

07

Study locations

69 sites
  • Site BE32005
    Tienen, Vlaams Brabant 3300, Belgium
  • Site CA15008
    Brampton, Ontario L6T 0G1, Canada
  • Site CA15010
    London, Ontario N5W 6A2, Canada
  • Site CA15003
    Sarnia, Ontario N7T 4X3, Canada
  • Site CA15012
    Montreal, Quebec H1M 1B1, Canada
  • Site CA15014
    Quebec City, Quebec G3K 2P8, Canada
  • Site CA15011
    Saint Charles Borromeee, Quebec J6E 2B4, Canada
  • Site CA15001
    Sherbrooke, Quebec J1L 0H8, Canada
  • Site CA15005
    Victoriaville, Quebec G6P 6P6, Canada
  • Site CA15002
    Quebec, G1S 2L6, Canada
  • Site CA15009
    Quebec, G1S 2L6, Canada
  • Site CA15007
    Quebec, G1W 4R4, Canada
  • Site CZ42007
    Tabor 3, Jihocesky 39003, Czechia
  • Site CZ42002
    Vodnany, Jihocesky 389 01, Czechia
  • Site CZ42008
    Brno, 603 00, Czechia
  • Site CZ42010
    Ceske Budejovice, 37001, Czechia
  • Site CZ42005
    Cheb, 350 02, Czechia
  • Site CZ42009
    Hradec Kralove, 500 02, Czechia
  • Site CZ42011
    Nachod, 54701, Czechia
  • Site CZ42003
    Olomouc, 772 00, Czechia
  • Site CZ42004
    Pisek, 397 01, Czechia
  • Site CZ42006
    Praha 2, 120 00, Czechia
  • Site DK45003
    Gandrup, Nordjylland 9362, Denmark
  • Site DK45002
    Odense, Syddanmark 5000, Denmark
  • Site DK45004
    Vejle, Syddanmark 7100, Denmark
  • Site DK45005
    Arhus C, 8000, Denmark
  • Site FI35801
    Kuopio, 02200, Finland
  • Site FI35803
    Oulu, 02200, Finland
  • Site FR33003
    La Rochelle, 17000, France
  • Site FR33001
    Nantes, 44093, France
  • Site DE49004
    Hamburg, 20253, Germany
  • Site DE49005
    Hamburg, 22159, Germany
  • Site DE49002
    Leipzig, 10026, Germany
  • Site DE49008
    Muechen, 12092, Germany
  • Site DE49006
    Schwerin, 19055, Germany
  • Site HU36002
    Debrecen, 4024, Hungary
  • Site HU36004
    Kecskemet, 6000, Hungary
  • Site HU36001
    Szekesfeherver, 8000, Hungary
  • Site IT39002
    Bologna, 12081, Italy
  • Site IT39006
    Pavia, 27100, Italy
  • Site NL31001
    Beek, Limburg 6191 JW, Netherlands
  • Site NL31004
    Rotterdam, 3051 GV, Netherlands
  • Site NO47001
    Hamar, 2317, Norway
  • Site PL48001
    Szczecin, Zachodniopomorskie 71-434, Poland
  • Site PL48003
    Bialystok, 15-224, Poland
  • Site PL48013
    Bydgoszcz, 85-048, Poland
  • Site PL48006
    Katowice, 40-065, Poland
  • Site PL48011
    Katowice, 40-156, Poland
  • Site PL48004
    Katowice, 40-301, Poland
  • Site PL48007
    Lublin, 20-064, Poland
  • Site PL48009
    Siedice, 08-110, Poland
  • Site PL48017
    Skierniewice, 96-100, Poland
  • Site PL48012
    Skorzewo, 60185, Poland
  • Site PL48010
    Zamosc, 22 400, Poland
  • Site ES34002
    Alcobendas, 28100, Spain
  • Site ES34005
    Centellas, 8540, Spain
  • Site ES34003
    Leganes, 28915, Spain
  • Site ES34001
    Madrid, 28041, Spain
  • Site SE46004
    Qerebro, 435 33, Sweden
  • Site SE46003
    Stockholm, 17176, Sweden
  • Site SE46002
    Uppsala, 435 33, Sweden
  • Site TR90002
    Konak, Izmir 35020, Turkey
  • Site TR90001
    Ankara, Mamak 06620, Turkey
  • Site TR90008
    Izmir, 35100, Turkey
  • Site GB44007
    Corby, Northamptonshire NN18 9EZ, United Kingdom
  • Site GB44004
    Shipley, Yorkshire BD18 3SA, United Kingdom
  • Site GB44002
    Coventry, CV3 4FJ, United Kingdom
  • Site GB44006
    Northwood, HA6 2RN, United Kingdom
  • Site GB44003
    Orpington, BR5 3QG, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Mar 2023, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2021
First posted
Sep 5, 2021
StartActual
Nov 8, 2021
Primary completionActual
Mar 27, 2023
CompletionActual
Apr 20, 2023
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05033886
Responsible party
Sponsor
First posted
Sep 5, 2021
Start date
Nov 8, 2021
Primary completion
Mar 27, 2023
Completion
Apr 20, 2023
Last update
Oct 26, 2024

Study contacts

Executive Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fezolinetant

Start the discussion